Maze Therapeutics, Inc.
MAZE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001842295
In the last 90 days, Maze Therapeutics, Inc. insiders filed 0 open-market purchases and 13 sales; 161 institutions reported holding it in 13F filings for Q2 2026, worth $1.75B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Maze Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 143
- +49 vs. Q3 2025
- Shares held
- 48.4M
- +5.40M (+12.6%) vs. Q3 2025
- Total value
- $2.00B
- +$889.5M (+79.8%) vs. Q3 2025
- New holders
- 57
- 46 more added
- Sold out
- 8
- 20 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MAZE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 161 | $1.75B |
| Q1 2026 | 165 | $1.54B |
| Q4 2025 | 143 | $2.00B |
| Q3 2025 | 94 | $1.11B |
| Q2 2025 | 75 | $476.7M |
| Q1 2025 | 68 | $441.4M |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Maze Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 173,816 | $7.20M | 0.24% | +173,816 | New |
| Charles Schwab Investment Management Inc | 175,969 | $7.29M | 0.00% | +8,041+4.8% | Added |
| Northern Trust Corp | 176,259 | $7.30M | 0.00% | −631−0.4% | Reduced |
| ADAR1 Capital Management, LLC | 179,532 | $7.44M | 0.56% | +153,487+589.3% | Added |
| Ensign Peak Advisors, Inc | 185,794 | $7.70M | 0.01% | +115,129+162.9% | Added |
| Alyeska Investment Group, L.P. | 196,124 | $8.13M | 0.02% | +71,124+56.9% | Added |
| Balyasny Asset Management LLC | 199,212 | $8.25M | 0.02% | −234,513−54.1% | Reduced |
| Parkman Healthcare Partners LLC | 209,266 | $8.67M | 0.83% | +9,266+4.6% | Added |
| Mass General Brigham, Inc | 239,994 | $9.94M | 1.23% | +239,994 | New |
| Morgan Stanley | 258,086 | $10.7M | 0.00% | +45,324+21.3% | Added |
| Washington University | 280,802 | $11.6M | 5.88% | +70,121+33.3% | Added |
| Eventide Asset Management, LLC | 324,041 | $13.4M | 0.21% | +324,041 | New |
| Driehaus Capital Management LLC | 378,015 | $15.7M | 0.11% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 409,372 | $17.0M | 0.45% | +57,497+16.3% | Added |
| Citadel Advisors LLC | 448,217 | $18.6M | 0.01% | +448,217 | New |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 457,535 | $19.0M | 0.61% | 00.0% | Unchanged |
| Matrix Capital Management Company, LP | 480,000 | $19.9M | 34.52% | −1,173,684−71.0% | Reduced |
| Bessemer Group Inc | 481,790 | $20.0M | 0.03% | 00.0% | Unchanged |
| Squadron Capital Management LLC | 490,000 | $20.3M | 9.06% | +490,000 | New |
| Foresite Capital Management IV, LLC | 522,657 | $21.7M | 9.43% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 527,281 | $21.9M | 0.00% | +53,732+11.3% | Added |
| State Street Corp | 533,005 | $22.1M | 0.00% | +148,303+38.6% | Added |
| Caligan Partners LP | 550,191 | $22.8M | 2.09% | +550,191 | New |
| Ikarian Capital, LLC | 644,680 | $26.7M | 3.46% | −96,145−13.0% | Reduced |
| FMR LLC | 728,605 | $30.2M | 0.00% | +72,991+11.1% | Added |
| Casdin Capital, LLC | 758,857 | $31.4M | 1.95% | 00.0% | Unchanged |
| ArrowMark Colorado Holdings LLC | 767,383 | $31.8M | 0.70% | +222,251+40.8% | Added |
| Marshall Wace, LLP | 847,472 | $35.1M | 0.03% | +69,771+9.0% | Added |
| Bellevue Group AG | 887,708 | $36.8M | 0.70% | +887,708 | New |
| Logos Global Management LP | 950,000 | $39.4M | 2.62% | −277,300−22.6% | Reduced |
| TRV GP V, LLC | 950,800 | $39.4M | 9.18% | 00.0% | Unchanged |
| Woodline Partners LP | 1,035,229 | $42.9M | 0.17% | 00.0% | Unchanged |
| General Catalyst Group Management, LLC | 1,035,910 | $42.9M | 19.35% | 00.0% | Unchanged |
| Alphabet Inc. | 1,388,583 | $57.5M | 2.23% | −1,023,888−42.4% | Reduced |
| VR Adviser, LLC | 1,548,569 | $64.2M | 3.17% | +317,800+25.8% | Added |
| Vanguard Group Inc | 1,697,015 | $70.3M | 0.00% | +362,060+27.1% | Added |
| AH Capital Management, L.L.C. | 1,702,225 | $70.5M | 4.46% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,287,155 | $94.8M | 0.00% | +971,139+73.8% | Added |
| Janus Henderson Group PLC | 3,142,587 | $130.2M | 0.06% | +2,390,713+318.0% | Added |
| ARCH Venture Management, LLC | 4,120,053 | $170.7M | 26.19% | 00.0% | Unchanged |
| Deep Track Capital, LP | 4,246,440 | $175.9M | 4.01% | +297,530+7.5% | Added |
| TRV GP IV, LLC | 4,473,958 | $185.4M | 72.65% | −1,600,000−26.3% | Reduced |
| Frazier Life Sciences Management, L.P. | 4,567,274 | $189.2M | 5.08% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −177,667−100.0% | Sold out |
| Nantahala Capital Management, LLC | 0 | $0 | 0.00% | −93,351−100.0% | Sold out |
| Harvard Management Co Inc | 0 | $0 | 0.00% | −92,396−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −16,165−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −14,487−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −13,742−100.0% | Sold out |
| Caption Management, LLC | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −307−100.0% | Sold out |